• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Johnson & Johnson drops 136-year old logo and renames Janssen

Johnson & Johnson drops 136-year old logo and renames Janssen

September 14, 2023 By Jim Hammerand

The 136-year-old Johnson & Johnson cursive logo and the new logo.
Johnson & Johnson is replacing its iconic cursive logo with a new look. [Logos courtesy of J&J]
Johnson & Johnson has rebranded with a new logo and a new name for its Janssen pharmaceutical business one year after renaming its medical device business — and just weeks after spinning off its consumer health business.

New Brunswick, New Jersey–based Johnson & Johnson (NYSE: JNJ) has replaced its 136-year-old logo — based on the signature of co-founder James Wood Johnson — with a “more modern logo and brighter red, keeping the iconic ampersand,” J&J CEO Joaquin Duato said today in a post on LinkedIn. The change is meant to call attention to J&J’s focus on innovative medicine and medtech, he said.

“Each letter is drawn in one pen stroke, creating a contrast that delivers both a sense of unexpectedness and humanity,” the company said in a news release, adding that the “refreshed, bright, and contemporary [red] speaks to the ability to urgently respond to health challenges, evolve with the times and set the pace,” while the updated ampersand “captures a caring, human nature. It now presents itself as a more globally recognizable symbol and represents the openness of the brand, as well as the connections that bring the company’s purpose to life.”

Johnson & Johnson’s old logo dated back to 1887, making it one of the longest-running corporate logos in history.

“Johnson & Johnson was founded on the principles of saving and improving lives,” company historian Margaret Gurowitz said in a 2017 blog post about the logo’s history. “James Wood Johnson took this mission so seriously that he literally signed the family name to the company’s products.”

Johnson & Johnson just last month completed the spinoff of its consumer health brand as a new independent company called Kenvue.

Johnson & Johnson MedTech is the second-largest medtech company in the world, according to Medical Design & Outsourcing‘s latest Medtech Big 100 ranking. Janssen, meanwhile, is the world’s fourth-largest pharmaceutical company, per the Pharma 50 ranking by MDO sister publication Drug Discovery & Development.

Read more at our sister publication Medical Design & Outsourcing.

 

Filed Under: Business/Financial News, Featured, News Well, Pharmaceutical Tagged With: Janssen, Janssen Pharmaceuticals, Johnson & Johnson

More recent news

  • Former Shockwave Medical CEO joins Solenic Medical’s board
  • Anaconda Biomed brings in $56 million
  • Precision Neuroscience raises $250M in Series D for its BCI
  • Fresenius discontinuing Chinese sales of 4008A hemodialysis system
  • Perfuze’s super-bore stroke catheter tops conventional, cyclic aspiration in bench study

About Jim Hammerand

Jim Hammerand is the managing editor of Arrowfly's MassDevice and Medical Design & Outsourcing, where he leads coverage of medtech innovation, design, engineering and manufacturing. He also contributes to our Devicetalks podcasts and live events. Hammerand has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then as managing editor of the Puget Sound Business Journal in Seattle. He holds degrees in journalism and management from the University of Minnesota and has won journalism awards from the Society of Professional Journalists, American Society of Business Publication Editors, and Trade, Association, Business Publications International. Connect with him on LinkedIn or by email at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy